Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 3/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18089423 | 1.00 | ALDH1A1 (0.34) | ALDH1A1LMNAKDM4EPOLBMAPK1 | |
| SCHEMBL19886698 | 0.91 | P2RX7 (0.36) | POLBP2RX7HSD17B10 | |
| SCHEMBL19886696 | 0.91 | P2RX7 (0.36) | POLBP2RX7HSD17B10 | |
| SCHEMBL18089741 | 0.85 | LMNA (0.33) | ALDH1A1LMNAKDM4EPOLB | |
| SCHEMBL19886693 | 0.83 | CAT (0.32) | HSD17B10 | |
| SCHEMBL21158427 | 0.83 | POLB (0.31) | POLB | |
| SCHEMBL18089738 | 0.83 | CAT (0.46) | — | |
| SCHEMBL18089666 | 0.81 | SMN1; SMN2 (0.40) | ALDH1A1KDM4EPOLBHSD17B10 | |
| SCHEMBL19886695 | 0.78 | P2RX7 (0.34) | P2RX7 | |
| SCHEMBL19886697 | 0.78 | FPR2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190211037-A1 | BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES IN ANTIMICROBIAL TREATMENT | REMPEX PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20180051041-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | THE MEDICINES COMPANY (SAN DIEGO), LLC | 2018-02-22 | — | — | US | disclosed |
| WO-2016149393-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180051041-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | BCL6B, BTD, BCL6 | ALDH1A1 1999/4885LMNA 1579/4885KDM4E 4553/4885 |
| US-20190211037-A1 | BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES IN ANTIMICROBIAL TREATMENT | BTD, BCL6B, BPGM | ALDH1A1 2886/4885LMNA 1733/4885KDM4E 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.